Key points:
- Dangerous India-made opioids are fuelling addiction in Ghana
- Regulatory failures and powerful interests enable the trade
- Threats and denials obstruct investigations into the crisis
BARELY a week ago, the BBC aired a shocking documentary revealing how deadly opioids made in India have flooded Ghana’s markets, creating a wave of addiction and social devastation. The film exposed a Mumbai-based pharmaceutical CEO, Vinod Sharma, proudly boasting about his company’s ability to flood West Africa with toxic painkillers under lax regulatory scrutiny.
Sharma, the head of Aveo Pharmaceuticals, openly confessed on camera to undercover journalists, describing how his drug concoction, Tafrodol, was designed to be dangerously addictive. His mixture of Tapentadol, a potent opioid, and Carisoprodol, a muscle relaxant, is so hazardous that it is banned or tightly controlled in many countries.
No government worldwide allows the legal sale of this combinat
ion due to its high abuse potential. Yet, Ghana has become a gateway for its distribution across West Africa, raising serious concerns about how such an illicit trade operates so openly.
Ghana: a ‘soft touch’ for drug smugglers
During the undercover sting, Sharma casually explained how Nigeria had tightened its borders to restrict the influx of these deadly drugs. However, he pointed out that Ghana’s looser controls made it the perfect entry point for smuggling. His advice to the supposed traffickers was simple:
- Avoid Nigeria—too risky.
- Use Ghana’s ports, where oversight is weaker.
- Move the drugs freely into the region.
If a foreign pharmaceutical CEO understands Ghana’s regulatory weaknesses well enough to exploit them, then the real question is: who in Ghana is making it so easy?
The BBC documentary captured harrowing scenes from cities like Tamale, where opioid addiction is rampant, devastating lives and entire communities. If so many of these dangerous pills are staying in Ghana, it is clear that domestic networks are deeply involved in this trade.
The role of Samospharma: importer or unwitting middleman?
The BBC report briefly mentioned a Ghanaian company, Samospharma, in connection with imports from Aveo Pharmaceuticals. However, in Ghana, this name is not a footnote—it is central to the discussion.
Samospharma is not a shadowy, unknown entity. It is a well-established company run by highly respected industry figures. Its founders are known for their work in pharmaceutical digitalisation and even serve on regulatory advisory boards. They also developed DrugNet, a digital platform intended to ensure high-quality medicine distribution and prevent substandard drug trade.
On paper, this company should be leading the fight against illicit drugs, not appearing in investigative reports about them. That is why its links to Aveo raised eyebrows.
When I shared my own findings on social media, expanding on months of BBC research and additional data I had gathered, the reaction was swift and aggressive.
Denials, legal threats, and a confusing narrative
Instead of offering a transparent response, Samospharma reacted with a strongly worded denial. The company categorically rejected any connection to Aveo, Westfin, or PRG Pharma.
I received an email threatening legal action, with a demand to delete my social media posts. This tactic, known as Strategic Lawsuits Against Public Participation (SLAPP), is increasingly used by corporations to silence journalists and analysts.
But here’s where things get murky:
- The Ghana Food & Drugs Authority (FDA) issued a statement contradicting Samospharma’s claims. The regulator confirmed that Samospharma had declared business relationships with Aveo and Westfin—but supposedly for non-opioid drugs.
- Customs records show imports of pharmaceutical products from Aveo to Samospharma. The volume and nature of these shipments remain unclear, but the link exists.
- The BBC documentary found Tafrodol for sale at a DrugNet-branded outlet. How did an illegal, unregistered opioid end up in a pharmacy linked to a company that claims to have no connection to the trade?
If Samospharma has never handled opioids, then where are the millions of pills in Ghana’s streets coming from?
Regulatory failure: how opioids keep flowing
In the wake of the documentary, India moved swiftly, banning the manufacture and sale of Tafrodol and freezing shipments headed to Ghana. Their swift action stands in stark contrast to Ghana’s response, where authorities have continued to move at a sluggish pace.
Despite evidence that:
- Tapentadol and Carisoprodol are illegal in Ghana.
- Aveo was caught actively shipping these drugs.
- Ghanaian import records show links to Indian exporters.
Customs and National Security have yet to publicly expose the local conduits involved.
The Ghana FDA has acknowledged the problem, yet the response from law enforcement has been muted. The same vague promises about ‘tightening controls’ have been repeated for years, while opioids continue to flow into the country.
A powerful force protecting the trade?
At the heart of this crisis is a bigger, darker question:
Who is protecting this trade in Ghana?
- The sheer volume of opioid imports suggests a well-organised network with influence at multiple levels of government.
- The silence from key regulatory agencies implies powerful people are involved.
- The inconsistencies in statements from companies and authorities suggest a web of deception designed to keep the truth hidden.
This is not just about pharmaceutical loopholes—this is a systemic failure involving politics, business, and possibly even security agencies.
If nothing changes, Ghana risks becoming West Africa’s opioid trafficking hub, with dire consequences for public health and regional security. The drug trade is already fuelling armed insurgencies in the Sahel, and unchecked, it could further destabilise the subregion.
The way forward: demand accountability
To fight this crisis, Ghana must act decisively:
- Conduct an independent forensic audit of import records to identify all opioid shipments into Ghana.
- Hold companies accountable, ensuring full transparency on their pharmaceutical dealings.
- Enforce strict border controls, preventing further opioid inflows.
- Strengthen consumer protection laws to protect journalists, researchers, and whistleblowers from SLAPP threats.
The evidence is clear: powerful interests want this trade to continue unchecked. But Ghana cannot afford to look away.
If the country’s
leaders fail to act, the next generation will pay the price—enslaved by addiction, controlled by crime networks, and abandoned by the very system meant to protect them.
Bright Simons is a Ghanaian social innovator, entrepreneur, writer, social and political commentator. He is the vice-president, in charge of research at IMANI Centre for Policy and Education. He is also the founder and president of mPedigree.
This article is republished from his blog, The Scarab. You may read the original version here.
